Corporate GovernanceMay 1, 2026, 04:23 PM
BioRestorative Therapies Approves 2025 Executive Cash Bonuses
AI Summary
BioRestorative Therapies' Compensation Committee approved cash bonuses for its executive officers for the year ended December 31, 2025. CEO Lance Alstodt received a $300,000 bonus, contributing to his total 2025 compensation of $2,409,167. VP of Research and Development Francisco Silva was awarded a $287,500 bonus, with his total compensation reaching $2,322,916. CFO Robert Kristal received a $140,000 bonus, bringing his total compensation to $801,750 for 2025. These discretionary bonuses for 2025 services are scheduled for payment in 2026.
Key Highlights
- Compensation Committee approved cash bonuses for executive officers for the year ended December 31, 2025.
- CEO Lance Alstodt received a $300,000 bonus for 2025, up from $275,000 in 2024.
- CEO Lance Alstodt's total 2025 compensation was $2,409,167.
- VP R&D Francisco Silva received a $287,500 bonus for 2025, up from $262,500 in 2024.
- VP R&D Francisco Silva's total 2025 compensation was $2,322,916.
- CFO Robert Kristal received a $140,000 bonus for 2025, up from $90,000 in 2024.
- CFO Robert Kristal's total 2025 compensation was $801,750.
- The approved 2025 discretionary bonuses are for services rendered in 2025 and will be paid in 2026.
Price Impact
More from BRTX